Osiris to Present Clinical and Scientific Studies at Desert Foot 2016
October 18 2016 - 4:30PM
Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative
medicine company focused on developing and marketing products to
treat conditions in wound care, orthopaedics and sports medicine,
will present advanced clinical and scientific research at the
Desert Foot Conference.
List of events supported by Osiris include:
On Wednesday, October 19:Dr. Lawrence Lavery, DPM, MPH will be
speaking on “The use of Viable Placental Membranes in Complex
Wounds” at the Breakfast Symposium from 7:15 a.m. to 8:00 a.m.
On Thursday, October 20:A Grafix® Workshop, which will provide
“hands on” experience and discussion of Grafix scientific and
clinical evidence, will take place from 10:05 a.m. to 1:05 p.m.
A CME lecture “Clinical and Scientific Advances in the Use of
Cryopreserved Placental Membranes in Complex Wounds” will be
presented by Dr. Gary Gibbons, MD, from 3:30 p.m. to 3:55
p.m.
On Friday, October 21:A Stravix™ workshop, which will provide
“hands on” experience and discussion of Stravix scientific and
clinical evidence, will take place from 10:30 a.m. to 1:30 p.m.
A lecture “The Use of Viable Cryopreserved Placental Tissue for
Surgical Applications” will be presented by Dr. Kyle Sundblad, DPM,
from 3:10 p.m. to 3:35 p.m.
On Saturday, October 22:Dr. Jonathan Brantley, DPM, will be
presenting a CME lecture “Placental Membranes: A Molecular Review”
from 8:20 a.m. to 8:45 a.m.
Dr. Alberto Abrebaya, DPM will be speaking on “The use of Viable
Placental Membranes in Complex Wounds” as part of the Indian Health
Service Limb Preservation Summit from 9:40 a.m. to 10:10 a.m.
Poster presentations:
“Case Study: Evaluation of the Use of Viable Cryopreserved Human
Placental Membrane for the Treatment of a Complex Diabetic Foot
Ulcer with Exposed Bone and Tendon” (by M Griages, S Kommareddy, L
Carranza and K Galli)
“Viable Cryopreserved Placental Allografts for the Treatment of
Post-Surgical Amputation Wounds in High Risk Patients” (by K
McGinness)
“The Use of a Viable Cryopreserved Umbilical Tissue Allograft
for Bunionectomy: Three Cases” (by J Brantley and J Richason)
“The Surgical Use of a Viable Cryopreserved Umbilical Tissue in
Partial Foot Amputations: a Three Patient Case Series” (by J
Brantley and J Richason)
“The Surgical Use of a Viable Cryopreserved Umbilical Tissue in
First Metatarsophalangeal Joint Arthrodesis: a Three Patient Case
Series” (by J Brantley and J Richason)
Osiris Therapeutics will also be exhibiting at the Desert Foot
meeting at booth 17.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a
world leader in researching, developing and marketing regenerative
medicine products that improve health and lives of patients and
lower overall healthcare costs. Having developed the world's first
approved stem cell drug, the company continues to advance its
research and development in biotechnology by focusing on innovation
in regenerative medicine - including bioengineering, stem cell
research and viable tissue based products. Osiris has achieved
commercial success with products in orthopaedics, sports medicine
and wound care, including BIO4®, Cartiform®, Grafix® , TruSkinTM
and StravixTM. Osiris, Grafix, Cartiform, TruSkin and Stravix are
trademarks of Osiris Therapeutics, Inc. BIO4® is a trademark of
Howmedica Osteonics Corp. More information can be found on the
company's website, www.Osiris.com (OSIR-G).
For additional information, please contact:
Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1834
OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Sep 2023 to Sep 2024